



Test every NSCLC patient

FOR ALL 10 GUIDELINE- RECOMMENDED BIOMARKERS

Wait for
test results
before first
line therapy—
they inform
treatment
selection

LUNG

Biomarker	Guideline- recommended	FDA- approved matched therapy	Associated therapy (overall response rate)
<i>EGFR</i>	●	●	TAGRISSO [®] , TARCEVA [®] , GILOTRIF [®] , IRESSA [®] , VIZIMPRO [®] (60–80%) ^{1–9}
<i>KRAS</i>	●	●	LUMAKRAS [™] , (37%) ¹⁰
<i>ALK</i>	●	●	ALECENSA [®] , ALUNBRIG [®] , ZYKADIA [®] , XALKORI [®] , LORBRENA [®] (40–80%) ^{11–17}
<i>ROS1</i>	●	●	XALKORI [®] , ROZLYTREK [™] , (72–78%) ^{18–19}
<i>BRAF</i>	●	●	TAFINLAR [®] + MEKINIST [®] , (65%) ²⁰
<i>MET</i> <i>exon 14 skipping</i>	●	●	TABRECTA [™] (41–68%) ²¹
<i>RET</i>	●	●	RETEVMO [™] (64–85%) ²²
<i>NTRK</i>	●	●	VITRAKVI [®] , ROZLYTREK [™] (57–75%) ^{18, 23}
<i>TMB</i>	●		KEYTRUDA [®] (29–37%) ²⁴
<i>ERBB2</i> (HER2)	●		KADCYLA [®] ^ (45%), HERCEPTIN [®] combinations (50%) ^{25, 26}
<i>MET</i> <i>amplifications</i>	●		XALKORI [®] (40%) ²⁷

**STOP
WAIT
TREAT**

Test every newly diagnosed advanced NSCLC patient for all 10 guideline-recommended biomarkers

Wait for complete results to determine the most effective therapy

Confidently choose the best possible first line treatment



Test every CRC patient

FOR ALL 6 GUIDELINE- RECOMMENDED BIOMARKERS

Wait for
test results
before first
line therapy—
they inform
treatment
selection

COLORECTAL

Biomarkers	Guideline- recommended	FDA- approved matched therapy	Associated therapy (response rate)
MSI-High	●	●	KEYTRUDA [®] , OPDIVO [®] + YERVOY [®] (40–50%)* ^{1, 2}
KRAS	●		Predicts lack of response to ERBITUX [®] , VECTIBIX [®]
NRAS	●		Predicts lack of response to ERBITUX [®] , VECTIBIX [®]
BRAF	●	●	BRAFTOVI [®] + ERBITUX [®] (20%)* ³
NTRK		●	VITRAKVI [®] , ROZLYTREK [™] (57–75%)* ^{4, 5}
ERBB2 (HER2)	●		HERCEPTIN [®] + PERJETA [®] , HERCEPTIN [®] + TYKERB [®] (27–32%)* ^{6, 7}
EGFR			Predicts lack of response to ERBITUX [®] , VECTIBIX [®]

**STOP
WAIT
TREAT**

Test every newly diagnosed advanced CRC patient for all 6 guideline-recommended biomarkers

Wait for complete results to determine the most effective therapy

Confidently choose the best possible first line treatment